Konstantinos Efthymiopoulos
Vorsitzender bei SynAffix BV
Profil
Konstantinos Efthymiopoulos is the founder of Epsilon-3 Bio Ltd, which was founded in 2010.
He is currently the Independent Chairman at SynAffix BV since 2016.
Dr. Efthymiopoulos's former jobs include being the Chief Executive Officer at Funxional Therapeutics Ltd., Chief Scientific Officer at Eurand, Inc., and holding Principal positions at Glaxo Wellcome, Inc., Glaxo, Inc., and Farmitalia Carlo Erba SRL.
Dr. Efthymiopoulos's education includes an MBA from the University of London, a graduate degree from the National & Kapodistrian University of Athens, and graduate and doctorate degrees from the University of Strasbourg.
Aktive Positionen von Konstantinos Efthymiopoulos
| Unternehmen | Position | Beginn |
|---|---|---|
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Vorsitzender | 07.01.2016 |
Ehemalige bekannte Positionen von Konstantinos Efthymiopoulos
| Unternehmen | Position | Ende |
|---|---|---|
Epsilon-3 Bio Ltd
 Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Gründer | - |
| Farmitalia Carlo Erba SRL | Corporate Officer/Principal | - |
| Glaxo, Inc. | Corporate Officer/Principal | - |
| Glaxo Wellcome, Inc. | Corporate Officer/Principal | - |
Eurand, Inc.
 Eurand, Inc. Pharmaceuticals: MajorHealth Technology Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Konstantinos Efthymiopoulos
| University of Strasbourg | Doctorate Degree |
| National & Kapodistrian University of Athens | Graduate Degree |
| University of London | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Funxional Therapeutics Ltd.
 Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Eurand, Inc.
Eurand, Inc. Pharmaceuticals: MajorHealth Technology Eurand, Inc. develops pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the United States. It's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste masking/fast dissolving formulations and drug conjugation. The company was founded in 1969 and is headquartered in Vandalia, OH. | Health Technology |
| Glaxo Wellcome, Inc. | Health Technology |
| Glaxo, Inc. | |
| Farmitalia Carlo Erba SRL | Health Technology |
Epsilon-3 Bio Ltd
Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |
